Story thread · 2 reports / 2 sources
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
247wallst.com · 4h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
Moderna (NASDAQ:MRNA) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at the European Society for Medical Oncology congress in Madrid. The stock is at $167.90, up 9% in Monday morning […]
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.